Biotech entity
pharma is the sole category represented across all 1 tracked stories. Nebraska Legislature is most often covered alongside John Arch, which appears in 1 of these 1 story. The tracked stories average 2 original sources each. Nebraska Legislature appears in 1 tracked Biotech story from February 20, 2026.
Last mentioned: Feb 20, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
pharma is the sole category represented across all 1 tracked stories. Nebraska Legislature is most often covered alongside John Arch, which appears in 1 of these 1 story. The tracked stories average 2 original sources each. Nebraska Legislature appears in 1 tracked Biotech story from February 20, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 9 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Nebraska Legislature. Shared-story counts are live from our verified record — not editorial picks.
Expected Implementation
New oversight mechanisms and fund distribution frameworks expected to take effect.
Priority Bill Announcement
Speaker John Arch designates opioid fund management and political accountability as 2026 priorities.
Initial Fund Distribution
First tranches of settlement funds begin arriving in Nebraska state accounts.
National Settlements Reached
Major opioid distributors and manufacturers reach multi-billion dollar settlements with states.
Nebraska Speaker John Arch has designated the management of opioid settlement funds and political accountability as top priorities for the 2026 legislative session. The move signals a push for greater transparency in how the state utilizes multi-million dollar payouts from pharmaceutical settlements.
Nebraska Legislature is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
